BiolineRX raises $24m in Nasdaq offering
The pulmonary device developer is believed to be in advanced talks with Covidien.
Pulmonary devices maker superDimension Inc. is in advanced talks with a major medical devices company to be acquired for over $300 million. superDimension, founded 16 years ago, has $30 million in annual sales.
It is believed that the buyer is Covidien plc (NYSE: COV), a spin off of Tyco International Ltd. (NYSE: TYC), which invested in superDimension's last financing round.
superDimension has raised $120 million from OrbiMed Advisors LLC, Pitango Venture Capital, Medica Venture Partner, Gemini Israel Funds, Concord Ventures, Evergreen Venture Partners, Niztanim, and Oxford Bioscience, as well as from strategic investors Covidien Ventures, Boston Scientific Inc. (NYSE: BSX), and Pfizer Inc. (NYSE: PFE; LSE: PFZ). The amount of money raised raises questions whether the company can be sold for an amount justifying the investment, but the company's sales and positive cash flow nevertheless suggest that investors can make at least a two-fold return on investment.
superDimesion's Electromagnetic Navigation Bronchoscopy receives full insurance indemnification for procedures. The device is mostly used to diagnose lung cancer. The company was founded in 1995 on the basis of navigation technology originally developed for planes, and subsequently used in toys. The company adapted it for navigation within the body, developing an endoscope for the bronchial tubes, for which there is no other available solution.
The system includes a sensor fitted at the tip of a catheter, which sends signals to three magnets placed on the patient's chest, and a magnetic sheet on which the patient lies. This creates a kind of GPS system for positioning the sensor within the lung. The device can be precisely sent to the suspected area, such as a tumor, take a biopsy, and mark the spot for subsequent precision radiation to reduce damage to surrounding healthy tissue.
Headquartered in Minneapolis, superDimension has 210 employees, including 23 in Herzliya. It also has an office in Dusseldorf, Germany.
Published by Globes [online], Israel business news - www.globes-online.com - on March 13, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.